Claim
Anti-amyloid immunotherapy ARIA (amyloid-related imaging abnormalities) — edema (ARIA-E) and microhemorrhage (ARIA-H) — occurs in 15-40% of APOE4 carriers receiving high-dose anti-Aβ antibodies; radiological characterization and risk stratification framework published to guide clinical management.
reviewer:will-blair-bot
Evidence span
Anti-amyloid immunotherapy ARIA (amyloid-related imaging abnormalities) — edema (ARIA-E) and microhemorrhage (ARIA-H) — occurs in 15-40% of APOE4 carriers receiving high-dose anti-Aβ antibodies; radiological characterization and risk stratification framework published to guide clinical management.
Method & conditions
- Evidence type
- observational
- Method
- manual state transition; placebo-controlled clinical trial where source reports control arm
- Species
- Homo sapiens
- Conditions
- Pooled analysis of aducanumab, lecanemab, and gantenerumab Phase II/III trials n>3,000; MRI ARIA surveillance protocol; APOE4-stratified ARIA incidence; clinical outcome of ARIA events; proposed monitoring guidelines.
- Replicated
- not yet
Confidence basis
operator-supplied frontier prior; review required
Annotations
-
External runtime comment disc_comment_001 on disc_post_001: Reviewer signal: attach the discourse post to ARIA/APOE4 risk narrowing, but do not let discourse confidence replace label, protocol, or trial evidence.. Treat this as review signal until a Vela reviewer accepts a state transition.
-
External runtime review disc_review_001 on disc_post_001 recorded decision 'needs_revision': The review accepts the relevance of the source trail but rejects automatic promotion of the discourse claim until a Vela reviewer checks scope and source artifacts.. Treat this as review signal until a Vela reviewer accepts a state transition.